167 related articles for article (PubMed ID: 27739445)
1. Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer.
Murphy AG; Casey R; Maguire A; Tosetto M; Butler CT; Conroy E; Reynolds AL; Sheahan K; O'Donoghue D; Gallagher WM; Fennelly D; Kennedy BN; O'Sullivan J
Sci Rep; 2016 Oct; 6():34523. PubMed ID: 27739445
[TBL] [Abstract][Full Text] [Related]
2. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.
Butler CT; Reynolds AL; Tosetto M; Dillon ET; Guiry PJ; Cagney G; O'Sullivan J; Kennedy BN
J Biol Chem; 2017 Mar; 292(9):3552-3567. PubMed ID: 28035003
[TBL] [Abstract][Full Text] [Related]
3. Phenotype-based Discovery of 2-[(E)-2-(Quinolin-2-yl)vinyl]phenol as a Novel Regulator of Ocular Angiogenesis.
Reynolds AL; Alvarez Y; Sasore T; Waghorne N; Butler CT; Kilty C; Smith AJ; McVicar C; Wong VH; Galvin O; Merrigan S; Osman J; Grebnev G; Sjölander A; Stitt AW; Kennedy BN
J Biol Chem; 2016 Apr; 291(14):7242-55. PubMed ID: 26846851
[TBL] [Abstract][Full Text] [Related]
4. Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors.
Kennedy SA; Morrissey ME; Dunne MR; O'Connell F; Butler CT; Cathcart MC; Buckley AM; Mehigan BJ; Larkin JO; McCormick P; Kennedy BN; O'Sullivan J
BMC Cancer; 2020 Oct; 20(1):952. PubMed ID: 33008336
[TBL] [Abstract][Full Text] [Related]
5. 1,4-dihydroxy quininib attenuates growth of colorectal cancer cells and xenografts and regulates the TIE-2 signaling pathway in patient tumours.
Butler CT; Kennedy SA; Buckley A; Doyle R; Conroy E; Gallagher WM; O'Sullivan J; Kennedy BN
Oncotarget; 2019 Jun; 10(38):3725-3744. PubMed ID: 31217905
[TBL] [Abstract][Full Text] [Related]
6. A sustained release formulation of novel quininib-hyaluronan microneedles inhibits angiogenesis and retinal vascular permeability in vivo.
Galvin O; Srivastava A; Carroll O; Kulkarni R; Dykes S; Vickers S; Dickinson K; Reynolds AL; Kilty C; Redmond G; Jones R; Cheetham S; Pandit A; Kennedy BN
J Control Release; 2016 Jul; 233():198-207. PubMed ID: 27086168
[TBL] [Abstract][Full Text] [Related]
7. Discovery and Development of the Quininib Series of Ocular Drugs.
Mahon N; Slater K; O'Brien J; Alvarez Y; Reynolds A; Kennedy B
J Ocul Pharmacol Ther; 2022; 38(1):33-42. PubMed ID: 35089801
[TBL] [Abstract][Full Text] [Related]
8. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms.
Wagner J; Kline CL; Zhou L; Khazak V; El-Deiry WS
J Exp Clin Cancer Res; 2018 Jan; 37(1):11. PubMed ID: 29357916
[TBL] [Abstract][Full Text] [Related]
10. E7080 (lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates antitumor activities against colorectal cancer xenografts.
Wiegering A; Korb D; Thalheimer A; Kämmerer U; Allmanritter J; Matthes N; Linnebacher M; Schlegel N; Klein I; Ergün S; Germer CT; Otto C
Neoplasia; 2014 Nov; 16(11):972-81. PubMed ID: 25425971
[TBL] [Abstract][Full Text] [Related]
11. Novel synthetic curcumin analogs as potent antiangiogenic agents in colorectal cancer.
Rajitha B; Nagaraju GP; Shaib WL; Alese OB; Snyder JP; Shoji M; Pattnaik S; Alam A; El-Rayes BF
Mol Carcinog; 2017 Jan; 56(1):288-299. PubMed ID: 27128654
[TBL] [Abstract][Full Text] [Related]
12. Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.
Fan Y; Peng A; He S; Shao X; Nie C; Chen L
J Chemother; 2013 Oct; 25(5):298-308. PubMed ID: 24070138
[TBL] [Abstract][Full Text] [Related]
13. Combination of copper-chelating agent, trientine, and methotrexate attenuates colorectal carcinoma development and angiogenesis in mice.
Yoshiji H; Yoshii J; Kuriyama S; Ikenaka Y; Noguchi R; Yanase K; Namisaki T; Kitade M; Yamazaki M; Fukui H
Oncol Rep; 2005 Jul; 14(1):213-8. PubMed ID: 15944792
[TBL] [Abstract][Full Text] [Related]
14. Pien Tze Huang inhibits tumor angiogenesis in a mouse model of colorectal cancer via suppression of multiple cellular pathways.
Shen A; Lin J; Chen Y; Lin W; Liu L; Hong Z; Sferra TJ; Peng J
Oncol Rep; 2013 Oct; 30(4):1701-6. PubMed ID: 23843018
[TBL] [Abstract][Full Text] [Related]
15. Tanshinone IIA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic microenvironments in human colorectal cancer.
Sui H; Zhao J; Zhou L; Wen H; Deng W; Li C; Ji Q; Liu X; Feng Y; Chai N; Zhang Q; Cai J; Li Q
Cancer Lett; 2017 Sep; 403():86-97. PubMed ID: 28602978
[TBL] [Abstract][Full Text] [Related]
16. Glutamate dependent NMDA receptor 2D is a novel angiogenic tumour endothelial marker in colorectal cancer.
Ferguson HJ; Wragg JW; Ward S; Heath VL; Ismail T; Bicknell R
Oncotarget; 2016 Apr; 7(15):20440-54. PubMed ID: 26943033
[TBL] [Abstract][Full Text] [Related]
17. Pregnancy-specific glycoprotein 9 (PSG9), a driver for colorectal cancer, enhances angiogenesis via activation of SMAD4.
Yang L; Hu S; Tan J; Zhang X; Yuan W; Wang Q; Xu L; Liu J; Liu Z; Jia Y; Huang X
Oncotarget; 2016 Sep; 7(38):61562-61574. PubMed ID: 27528036
[TBL] [Abstract][Full Text] [Related]
18. Ursolic acid inhibits colorectal cancer angiogenesis through suppression of multiple signaling pathways.
Lin J; Chen Y; Wei L; Hong Z; Sferra TJ; Peng J
Int J Oncol; 2013 Nov; 43(5):1666-74. PubMed ID: 24042330
[TBL] [Abstract][Full Text] [Related]
19. DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Oncotarget; 2016 Sep; 7(39):63124-63137. PubMed ID: 27517319
[TBL] [Abstract][Full Text] [Related]
20. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
